Consistent with the 18-fold increase in SSAT activity in the TRAMP/SSAT bigenics, prostatic N 1 -acetylspermidine and putrescine pools were remarkably increased relative to TRAMP mice while spermidine and spermine pools were minimally affected due to a compensatory 5-to 7-fold increase in biosynthetic enzymes activities. The latter led to heightened metabolic flux through the polyamine pathway and an associated ~70% reduction in the SSAT cofactor acetylCoA and a ~40% reduction in the polyamine aminopropyl donor S-adenosylmethionine in TRAMP/SSAT compared to TRAMP prostatic tissue. In addition to elucidating the antiproliferative and metabolic consequences of SSAT overexpression in a prostate cancer model, these findings provide genetic support for the discovery and development of specific small molecule inducers of SSAT as a novel therapeutic strategy targeting prostate cancer.
INTRODUCTION
Although prostate cancer can be clinically managed in its early phases, the inability to control the more aggressive late-stage disease has prompted the search for novel therapies. We became interested in the possibility that strategies targeting polyamine homeostasis may be effective against prostate cancer. The prostate has the highest level of polyamine biosynthesis of any tissue and it is the only tissue in which polyamines are purposely synthesized for export.
More particularly, massive amounts of polyamines are excreted by the prostate into semen.
Thus, we reasoned that polyamine homeostasis may be altered in the prostate relative to other tissues and that tumors derived from this gland may exhibit atypical regulatory responses to polyamine analogues and inhibitors (1) . Additional rationale for targeting polyamines in prostate cancer derives from a recent meta-analysis of four independent microarray datasets comparing gene expression profiles of benign and malignant patient prostate samples showing that polyamine metabolism was the most systematically affected of all biochemical and signaling pathways (2) . Genes that supported polyamine biosynthesis were up-regulated while those that detracted from biosynthesis were down-regulated. The findings agree with earlier clinical studies showing a significant increase in ornithine decarboxylase (ODC) 6 and Sadenosylmethionine (SAMDC) transcripts in human prostatic cancer relative to benign hyperplasia (3).
Polyamines have been targeted in anticancer strategies for some time (4) . Various antagonists such as the ODC inhibitor, α-difluoromethylornithine (DFMO), SAMDC inhibitor (SAM486), and the polyamine analogue, N 1 ,N 11 -diethylnorspermine (DENSPM) have undergone clinical testing as therapeutic and/or preventive agents (5, 6) . Recognizing the unique physiology of the prostate gland, Heston and collaborators proposed that polyamine inhibitors may be particularly effective against prostate cancer (7, 8) . In support of this concept, Gupta et al. (9) showed that DFMO is effective in depleting polyamine pools and in preventing development of prostate cancer in the TRansgenic Adenocarcinoma of Mouse Prostate (TRAMP) model (10) .
Targeting polyamines has traditionally involved interference with or down-regulation of polyamine biosynthesis with small molecule inhibitors or analogues, respectively. As an alternative to blocking biosynthesis, we propose that activation of polyamine catabolism by inducing the rate-limiting enzyme spermidine/spermine N 1 -acetylspermine transferase (SSAT) may offer distinct advantages. The approach derives from our studies of the polyamine analogue DENSPM which, in addition to down-regulating ODC and SAMDC, very potently up-regulates SSAT in tumor cells and tissues (11) (12) (13) (14) . The latter was shown to occur to a greater degree in human tumor xenografts than in normal host tissues (15) . Correlations between SSAT induction and growth inhibition have been repeatedly suggested by early work in a variety of tumor types (14, 16, 17) . Recently, that relationship was more precisely defined by the finding that SSATtargeted siRNA minimizes analogue mediated enzyme induction and at the same time, prevents polyamine pool depletion and apoptosis (18, 19) .
We have previously reported that conditional over-expression of SSAT in MCF-7 breast carcinoma cells leads to polyamine pool depletion and growth inhibition (20) . As a prelude to the present study, we showed that conditional enzyme expression in LNCaP prostate carcinoma cells caused growth inhibition that differed from that seen in MCF-7 cells in that it was not accompanied by polyamine pool depletion (21) . Instead, cells averted the latter by increasing polyamine biosynthesis at the levels of ODC and SAMDC activities causing heightened metabolic flux through the biosynthetic and catabolic pathways. In a critical experiment, it was shown that interruption of flux by blocking ODC activity prevented growth inhibition (21) .
Additional studies concluded that growth inhibition deriving from overexpression of SSAT was probably attributable to over-production of pathway products such as acetylated polyamines or to depletion of polyamine precursor metabolites such as S-adenosylmethionine (SAM) and/or the SSAT cofactor, acetyl-CoA (21) . Whatever the downstream mechanism, these in vitro data suggest that activation of polyamine catabolism by selective induction of SSAT may constitute an effective antitumor strategy against prostate cancer.
The goal of the present study is to further validate the above concept by providing critical in vivo evidence based on a genetic approach. For this purpose, we utilized the TRAMP model that is genetically engineered to develop prostate cancer (10, 22, 23) . Cross-breeding these mice with SSAT transgenic mice that systemically overexpress the enzyme (24) resulted in a profound suppression of prostate tumor outgrowth that may be related to consequences emanating from depletion of acetyl-CoA pools.
EXPERIMENTAL PROCEDURES

Materials.
The polyamines putrescine (Put), spermidine (Spd), spermine (Spm) and acetylated polyamine N 1 -acetylspermidine (AcSpd) were purchased from Sigma Chemical Co. (St. Louis, MO). Acetyl-CoA was also purchased from Sigma Chemical Co. and solubilized as described by Liu et al. (25) .
Breeding and Screening of Transgenic Animals. TRAMP mice (10), heterozygous for the transgene rat probasin-T antigen (PB-Tag) (lineage of founder 8247; Jackson Laboratory, Bar
Harbor, ME) were maintained in a pure C57BL/6 background. Mouse-tail DNA was isolated using the DNeasy ® Tissue Kit (Qiagen Inc., Valencia, CA). Genotyping of TRAMP animals was performed by PCR according to the Jackson Laboratory protocol.
We previously generated mice that systemically overexpressed SSAT under its endogenous murine gene promoter (24) . SSAT transgenics, in the CD2F1 genetic background (24) , were back-crossed for >8 generations into C57BL/6, the same genetic background as the TRAMP mouse. The SSAT transgenics are characterized by pronounced hair loss by 3-4 wk of age (24) , making genotyping unnecessary. Since female SSAT transgenic mice are infertile, and male SSAT transgenic mice have normal reproductive capabilities, the latter were cross-bred with female TRAMP mice to generate the double transgenics used in this study. (27) . Once GU tracts were grossly examined and documented by fixed angle photography, the dorsal (DP), lateral (LP), ventral (VP), and anterior (AP) lobes of the prostate, as well as the seminal vesicles were microdissected and placed into multichamber cassettes for fixation in 4% paraformaldehyde for 4 hr at 4ºC after which, they were paraffin embedded, sectioned at 5 µm and stained with hematoxylin and eosin (H&E). H&E slides were reviewed by two experienced morphologists without knowledge of the genotype or age of the mice. Each prostatic lobe (dorsal, lateral, ventral, and anterior) was scored according to the grading system established by 
RESULTS AND DISCUSSION
The goal of this study was to provide in vivo genetic validation for the concept that activating polyamine catabolism at the level of SSAT will give rise to an antitumor response due to homeostatic perturbations in polyamine metabolism. The effort was catalyzed by our recent
reports showing that conditional overexpression of SSAT inhibits in vitro growth of both MCF-7 breast carcinoma cells (20) and LNCaP prostate carcinoma cells (21) . Consistent with these
findings, we now demonstrate that overexpression of SSAT markedly suppresses tumor outgrowth of early and advanced prostatic cancer in TRAMP mice. As will be discussed, this may be due to unusual sensitivity of prostate-derived tumors to polyamine perturbations and/or to novel metabolic disturbances emanating from compensatory responses to activated polyamine catabolism.
SSAT overexpressing transgenic male mice were crossbred with female TRAMP mice to yield 4 cohorts of offspring: wild-type, SSAT transgenics, TRAMP and TRAMP/SSAT bigenics. At 15 wk of age, prostate and liver tissues were excised from wild-type, SSAT, TRAMP and TRAMP/SSAT mice to confirm SSAT mRNA expression and enzyme activity. As shown in Figure 1 , prostate gland SSAT mRNA levels were elevated 32-and 35-fold in both SSAT and TRAMP/SSAT cohorts, respectively, relative to wild-type mice. Consistent with SSAT gene overexpression prostatic enzyme activity in both SSAT and TRAMP/SSAT mice was elevated by ~18-fold. SSAT mRNA in liver of SSAT and TRAMP/SSAT mice was increased 20-and 30-fold over wild-type mice, but unlike the prostate, enzyme activities were only increased 3-and 2-fold, presumably, due to tissue-specific differences in translational control (24) . The data confirm that overexpression of SSAT occurs in the prostate of transgenebearing mice.
Longitudinal assessment of the prostate by MR imaging was used to monitor tumor appearance and development in representative TRAMP animals. Genitourinary (GU) tumors were first apparent at ~20 wk of age in TRAMP animals. By 30 wk, all TRAMP mice had visible prostate tumors that, with time, infiltrated the seminal vesicles as is typical in the pure C57BL/6 genetic background (10, 22, 27, 34) . As observed using MR imaging and confirmed at necropsy, some TRAMP mice exhibited predominantly prostatic tumors, while the majority showed significant prostate tumors with seminal vesicle involvement. Both pathologies were reduced in the TRAMP/SSAT mice. On the basis of tumor size in TRAMP mice, the experimental endpoint was set at week 30.
The suppressive effect of SSAT overexpression on tumor out-growth is apparent in comparisons of dissected genitourinary (GU) tracts shown in Figure 2A . Gross examination of both wild-type and SSAT animals revealed GU tracts that were generally uniform in size and shape. As graphed in Figure 2B , GU tracts of the SSAT mice were significantly smaller (178 ± 30 mg) than those of the wild type mice (504 ± 11 mg) despite close similarities in body weight (Fig. 3A) . Consistent with previous reports (28) , disease in the TRAMP mouse was apparent in the dorsal, lateral and ventral lobes with substantial seminal vesicle involvement, and it tended to be heterogeneous among mice. When all prostate lobes were averaged (Table 1) , the mean TRAMP/SSAT mouse grade (4.2) was significantly lower than that of the TRAMP mice (5.0) suggesting interference with disease progression. A similar trend was also seen at 36 wk. Thus, while the major effect of SSAT overexpression is most obviously manifested as suppression of tumor outgrowth, there is also a delay in tumor progression. Because prostatic disease in the C57BL/6 background infiltrated the seminal vesicles, we derived an index to quantify overall GU disease. Thus, the average histological grades of the four lobes were averaged and then multiplied by the mean GU tract weight to derive a GU disease index for each cohort of animals ( Table 1) . Based on this determination, the disease index at 30-wks in the TRAMP/SSAT mice (1.51 ± 0.27) was found to be ~5-fold lower than that of the TRAMP mice (7.44 ± 1.12).
The suppression of tumor outgrowth seen here is consistent with a previous report showing that SSAT transgenic animals are more resistant to the development of skin papillomas under the two-stage skin carcinogenesis protocol (35) . However, both studies differ from a report indicating that transgenic overexpression of SSAT in the mouse skin causes an increase in chemically-induced tumor incidence (36) . This is unexpected since observations over the last seven years find that spontaneous tumor formation was not increased in SSAT transgenic mice (unreported observation). While the basis for this discrepancy is not immediately apparent, it is reasonable to consider that it may be due to promoter dictated gene expression and/or to tissue- Gupta et al. (9) found that DFMO in the drinking water of TRAMP mice from 8 to 28 wk of age reduced the weight of the prostate and GU tracts by ~60% at 28 wk while at the same time, eliminating distant metastases. This is less than the 75% difference in GU weights seen here at 30 wk. It is interesting to consider, however, that the Gupta study achieved the antitumor effect by pharmacologically decreasing polyamine biosynthesis while the present study appears to have achieved a comparable effect by increasing polyamine biosynthesis secondary to SSAT overexpression as will be discussed below. To determine how polyamine-related events contribute to suppression of tumor outgrowth, we measured the activities of SSAT and the biosynthetic enzymes, ODC, and SAMDC, as well as tissue polyamine and acetylated polyamine pools in both tumors and liver at 30 wk. As shown in Table 2 , SSAT activity in the prostate tissue was elevated ~20-fold in both the SSAT and TRAMP/SSAT mice compared to wild-type and TRAMP mice. The more modest 2-to 3-fold enhancement of SSAT activity in the liver despite a 20-fold increase SSAT mRNA (38, 39) , would seem to reflect tissue-specific translational control of this gene (38, 39) . Increases in SSAT activity were accompanied by a profound (i.e. >10-fold) rise in biosynthesis at the level of ODC and SAMDC activities in both the prostate and the liver. As previously described in LNCaP cells (21) , this represents a compensatory homeostatic response to activated polyamine catabolism. These changes in enzyme activities produced significant disturbances in tissue polyamine profiles, particularly involving the acetylated polyamines. Although AcSpm remained undetectable, AcSpd increased from undetectable levels in the prostate and liver of wild-type and TRAMP mice to extraordinarily high levels in SSAT and TRAMP/SSAT mouse tissues. Another major finding was the accumulation of huge amounts of Put in both prostate and liver of SSAT-bearing mice, presumably, due to the back-conversion of Spd due to SSAT overexpression and to the forward conversion of ornithine due to high levels of ODC activity.
Despite the generation of large amounts of AcSpd, Spd pools remained relatively unaffected in the TRAMP/SSAT prostate tumors relative to TRAMP mice while Spm decreased by ~33%, presumably due to back-catabolism. This modest reduction in prostatic Spm pools hardly seems sufficient to account for the observed tumor growth suppression. As in LNCaP cells (21) , the data suggest that the compensatory increase in polyamine biosynthesis and related metabolic flux may be playing a critical role in growth inhibition. More particularly, SSAT overexpression leads to massive acetylation and potential loss of cellular polyamines. To maintain a normal polyamine profile, the system responds by up-regulating ODC and SAMDC activities leading to a heightened metabolic flux through both arms of the pathway. Thus, ornithine is more rapidly converted to Spd and Spm which in turn are more rapidly acted upon by SSAT to yield acetylated products. These findings are nearly identical to those elucidated in SSAT over-expressing LNCaP prostate carcinoma cells (21) where activation of polyamine catabolism was also accompanied by increased polyamine biosynthesis. As a result, the Spd and Spm pools were unaffected despite massive production of acetylated polyamines. In a defining experiment, the relationship between this compensatory increase in ODC and growth inhibition in LNCaP cells was confirmed by the finding that growth inhibition is prevented by treatment with the ODC inhibitor DFMO. The compensatory increase in ODC and SAMDC activities in response to activated polyamine catabolism has been previously noted in various other tissues of the SSAT mouse (24) and thus, is not unique to the prostate. The consequence of this effect, however, seems to be selective for both the male and female reproductive tracts since as noted above, these are the only two organs that are under-developed in SSAT transgenic mice.
Guided by earlier findings in the LNCaP system (21), we examined the downstream consequences connecting heightened metabolic flux to growth inhibition or in this case, suppression of tumor outgrowth (Fig. 1) . Hence, we focused on two classes of contributing events: toxic accumulation of metabolic products such as acetylated polyamines or depletion of critical metabolic precursors such as the aminopropyl donor SAM and/or the SSAT cofactor, acetyl-CoA. Among the accumulated products, Put and AcSpd represent possible sources of tumor growth inhibition in bigenic mice and were not investigated further. On the precursor depletion side, the polyamine aminopropyl donor SAM and the SSAT cofactor acetyl-CoA were found to be significantly decreased in both SSAT and TRAMP/SSAT prostates. SAM pools were 40% lower in bigenic than in TRAMP mice (Fig. 4B) . Even greater decreases were observed in the livers of SSAT-transgenics. Although SAM is known to be critically involved in methylation reactions, it seems doubtful that the 40% pool reduction seen in the prostate tumors was growth-limiting since the liver showed a much greater decrease (85%) without obvious pathology and since the polyamines synthesized using SAM, Spd and Spm, were not decreased in the prostate tumors of bigenics. This does not, however, exclude the possibility that SAM is being preferentially diverted to polyamine biosynthesis at the expense of methylation reactions.
Attention was then focused on acetyl-CoA, which in addition to serving as a cofactor to SSAT, is critically involved in fatty acid metabolism, cholesterol synthesis and chromatin structure involving histone acetylation. Acetyl-CoA was impressively ~90% lower in prostates of SSAT mice than in wild-type mice and ~70% lower in TRAMP/SSAT mice than in TRAMP mice (Fig. 4C) . By contrast, the acetyl-CoA pools in the livers of SSAT-bearing mice relative to nonSSAT-bearing mice were not similarly affected which is consistent with the primary role of this organ in fat metabolism. Given the metabolic significance of acetyl-CoA, it is conceivable that the 70% reduction in pools seen in TRAMP/SSAT mice could impact negatively on tumor growth. Indication that such perturbations may, in fact, interfere with fatty acid metabolism is strongly suggested by the observation that SSAT mice have markedly depleted abdominal and subdermal fat stores relative to wild-type mice (Fig. 5) , an effect not previously reported in the original characterization of these mice (24) .
As previously reported (21), acetyl-CoA was also found to be decreased during conditional overexpression of SSAT in LNCaP cells, although not to the same extent as seen here. In cells, the effect correlated closely with growth inhibition but it could not be causally (13, 47, 48) . Although such analogues are potent inducers of SSAT, they also down-regulate polyamine biosynthesis, a response that would preclude heightened metabolic flux which appears to be critical to the antiproliferative effect seen here (21) . In addition, down-regulation of polyamine biosynthetic enzymes may account for the toxicity of polyamine analogues (12, 15, 16) , since it is known that, unlike SSAT overexpression which permits normal development except for hair-loss and hypo-developed reproductive tracts, ODC knock-out is embryonically lethal in mice (49) . When taken together with the current data, these rationale present a compelling case for the discovery and Table 1 for detailed analysis). 
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GU Disease Index = (average overall grade + average highest grade) x average GU weight, as determined per animal. See Figure 3A for representative histology of the prostate epithelium. The average prostate total grade for wild-type or SSAT mice was 2.0 Statistical significance (P-value) was determined by analysis of variance (ANOVA) with Fisher's PLSD test. 
